JAOA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


JAOA • Vol 104 • No 4 • April 2004 • 157-163
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, D. H.
Right arrow Articles by Craig, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, D. H.
Right arrow Articles by Craig, T. J.

ORIGINAL CONTRIBUTION

Early Diagnosis Is Key in Vancomycin-Induced Linear IgA Bullous Dermatosis and Stevens-Johnson Syndrome

Douglas H. Jones, MS; Michael Todd, MD; Timothy J. Craig, DO

From the Milton S. Hershey Medical Center at Pennsylvania State University in Hershey, Pa.

Address correspondence to Timothy J. Craig, DO, Pennsylvania State University, The Milton S. Hershey Medical Center, Pulmonary, Allergy, and Critical Care Medicine, HO41, 500 University Dr., PO Box 850, Hershey, PA 17033-0850. E-mail: tcraig{at}psu.edu

Background: With the emergence of highly resistant betalactam gram-positive organisms, vancomycin hydrochloride usage has increased considerably. Consequently, adverse drug reactions, including unfavorable cutaneous events, have also increased. Important adverse skin reactions are linear IgA bullous dermatosis (LABD) and Stevens-Johnson syndrome (SJS). These blistering disorders can have clinical manifestations that are difficult to distinguish; however, it is important to make the distinction because treatment and prognosis are different.

Objective: The purpose of this study is to review the literature on LABD and SJS and compare important differentiating characteristics to assist physicians in making the correct diagnosis.

Methods: The authors used MEDLINE to search for all published studies on vancomycin adverse events, and combined LABD, SJS, exanthema, and skin rashes each separately with vancomycin adverse events. Furthermore, the authors searched PubMed for all meta-analyses and randomized controlled clinical trials relating to treatment of patients with SJS.

Results: Clinically, LABD and SJS both present similarly with bullae. Diagnosis is made by use of perilesional skin biopsy and direct immunofluorescence. Direct immunofluorescence shows linear IgA deposition along the basement membrane zone in LABD, whereas this is absent in SJS. The treatment for both vancomycin-induced SJS and vancomycin-induced LABD is prompt discontinuation of the drug. However, if SJS is diagnosed early, systemic corticosteroids appear to decrease morbidity.

Conclusions: In cases of SJS or LABD that are difficult to distinguish clinically, the authors recommend performing a skin biopsy and direct immunofluorescence early to confirm the diagnosis so that effective treatment can be instituted.




This article has been cited by other articles:


Home page
Arch DermatolHome page
S. E. Billet, K. R. Kortuem, L. E. Gibson, and R. el-Azhary
A Morbilliform Variant of Vancomycin-Induced Linear IgA Bullous Dermatosis
Arch Dermatol, June 1, 2008; 144(6): 774 - 778.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Osteopathic Association.